Person: Abramson, Jeremy
Loading...
Email Address
AA Acceptance Date
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
Abramson
First Name
Jeremy
Name
Abramson, Jeremy
4 results
Search Results
Now showing 1 - 4 of 4
Publication Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation(Public Library of Science, 2018) Hogan, Louise E.; Hanhauser, Emily; Hobbs, Kristen S.; Palmer, Christine D.; Robles, Yvonne; Jost, Stephanie; LaCasce, Anne S.; Abramson, Jeremy; Hamdan, Ayad; Marty, Francisco; Kuritzkes, Daniel; Henrich, Timothy J.Background: Human Herpes Virus 8 (HHV8) can cause Kaposi’s Sarcoma (KS) in immunosuppressed individuals. However, little is known about the association between chemotherapy or hematopoietic stem cell transplantation (HSCT), circulating HHV8 DNA levels, and clinical KS in HIV-1-infected individuals with various malignancies. Therefore, we examined the associations between various malignancies, systemic cancer chemotherapy, T cell phenotypes, and circulating HHV8 DNA in 29 HIV-1-infected participants with concomitant KS or other cancer diagnoses. Methods: We quantified HHV8 plasma viral loads and cell-associated HHV8 DNA and determined the relationship between circulating HHV8 DNA and lymphocyte counts, and markers of early and late lymphocyte activation, proliferation and exhaustion. Results: There were no significant differences in plasma HHV8 DNA levels between baseline and post-chemotherapy time points or with the presence or absence of clinical KS. However, in two participants circulating HHV8 DNA increased following treatment for KS or HSCT for lymphoma,. We observed an approximately 2-log10 reduction in plasma HHV8 DNA in an individual with KS and multicentric Castleman disease following rituximab monotherapy. Although individuals with clinical KS had lower mean CD4+ T cell counts and percentages as expected, there were no significant associations with these factors and plasma HHV8 levels. We identified increased proportions of CD8+ and CD4+ T cells expressing CD69 (P = 0.01 & P = 0.04 respectively), and increased CD57 expression on CD4+ T cells (P = 0.003) in participants with detectable HHV8. Conclusion: These results suggest there is a complex relationship between circulating HHV8 DNA and tissue-based disease in HIV-1 and HHV8 co-infected individuals with various malignancies.Publication Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary?(Impact Journals LLC, 2015) Ok, Chi Young; Ye, Qing; Li, Ling; Manyam, Ganiraju C.; Deng, Lijuan; Goswami, Rashmi R.; Wang, Xiaoxiao; Montes-Moreno, Santiago; Visco, Carlo; Tzankov, Alexandar; Dybkaer, Karen; Zhang, Li; Abramson, Jeremy; Sohani, Aliyah R.; Chiu, April; Orazi, Attilio; Zu, Youli; Bhagat, Govind; Richards, Kristy L.; Hsi, Eric D.; Choi, William W.L.; van Krieken, J. Han; Huh, Jooryung; Ponzoni, Maurilio; Ferreri, Andrés J.M.; Zhang, Shanxiang; Parsons, Ben M.; Xu, Mina; Møller, Michael B.; Winter, Jane N.; Piris, Miguel A.; Xu-Monette, Zijun Y.; Medeiros, L. Jeffrey; Young, Ken H.Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (EBV+ DLBCL-e) is a molecularly distinct variant of DLBCL, characterized by a monoclonal B-cell proliferation that occurs in patients >50 years of age without a history or clinicopathologic evidence of immunodeficiency. However, patients with EBV+ DLBCL younger than 50-years-old also exist in Western countries. We evaluated the clinicopathologic, immunophenotypic and genetic features in Cacausian patients with EBV+ DLBCL who are ≤50 years of age and compared this patient group to patients who are >50 years. In patients who are ≤50 years, less frequent expression of BCL6 and a trend of more frequent expression of CD30 and pSTAT3 were found in patients with EBV+ DLBCL. In patients who are >50 years, common expression of CD30, p50, pSTAT3 and less frequent expression of BCL6 were observed. Older patients also more commonly had a poor performance status (ECOG≥2). Comparing EBV+ DLBCL patients in ≤50 years versus >50 years, both groups had similar clinicopathologic, immunophenotypic and genetic features. Gene expression profiling, microRNA profiling and treatment outcome of the younger patients with EBV+ DLBCL was not distinctive from tumors in older patients. Based on our data, we suggest that the arbitrary age cutoff for EBV+ DLBCL is unnecessary and should be eliminated in the WHO lymphoma classification scheme.Publication Holographic Assessment of Lymphoma Tissue (HALT) for Global Oncology Field Applications(Ivyspring International Publisher, 2016) Pathania, Divya; Im, Hyungsoon; Kilcoyne, Aoife; Sohani, Aliyah R.; Fexon, Lioubov; Pivovarov, Misha; Abramson, Jeremy; Randall, Thomas; Chabner, Bruce; Weissleder, Ralph; Lee, Hakho; Castro, CesarLow-cost, rapid and accurate detection technologies are key requisites to cope with the growing global cancer challenges. The need is particularly pronounced in resource-limited settings where treatment opportunities are often missed due to the absence of timely diagnoses. We herein describe a Holographic Assessment of Lymphoma Tissue (HALT) system that adopts a smartphone as the basis for molecular cancer diagnostics. The system detects malignant lymphoma cells labeled with marker-specific microbeads that produce unique holographic signatures. Importantly, we optimized HALT to detect lymphomas in fine-needle aspirates from superficial lymph nodes, procedures that align with the minimally invasive biopsy needs of resource-constrained regions. We equipped the platform to directly address the practical needs of employing novel technologies for “real world” use. The HALT assay generated readouts in <1.5 h and demonstrated good agreement with standard cytology and surgical pathology.Publication Unanswered Questions in HIV Hematology(Hindawi Publishing Corporation, 2012) Leitch, Heather A.; Abramson, Jeremy; Cheung, Matthew C.; Hicks, Lisa K.